Home / Innere Medizin / Hämatologie und internistische Onkologie / ASH 2019: Erstes kuratives Konzept bei multiplem Myelom?

Dr. Sabine Burger

ASH 2019: Erstes kuratives Konzept bei multiplem Myelom?

OÄ. Dr. Sabine Burger von der 3. Medizinischen Abteilung am Hanusch-Krankenhaus, gibt einen Überblick über die neuen Myelom-Studien vom ASH 2019, darunter ein möglicherweise kuratives Konzept und eine neue Methode die Patienten häufige Knochnemarkspunktionen ersparen könnte.

Cookies aktivieren

Um das Video anzusehen, müssen Sie Statistikcookies akzeptieren.

Einstellungen verwalten

Quelle: ASH Annual Meeting 2019

Abstracts die im Video diskutiert werden: 

Vorhees P et al., Abstract 691
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Moreau P et al., Abstract 692
Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Bahlis N et al., Abstracts 1875
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Scheid C et al., Abstract 3308
Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Costa LJ et al., Abstract 3125
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

Madduri D et al., Abstract 577
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)